Doxorubicin

• CAT Number: I002769
• CAS Number: 23214-92-8
• Molecular Formula: C27H29NO11
• Molecular Weight: 543.52
• Purity: ≥95%
• Synonyms: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• Target: Topoisomerase
• Solubility: 25 mM in DMSO, 50 mM in H2O
• Storage: Store at RT
• InChI: InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
• InChIKey: AOJJSUZBOXZQNB-TZSSRYMLSA-N
• SMILES: CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O

Doxorubicin (CAT: I002769) is a potent anthracycline chemotherapy drug widely used in the treatment of various types of cancer, including breast cancer, lung cancer, and leukemia. It exerts its anticancer effects by intercalating with DNA, inhibiting DNA and RNA synthesis, and inducing DNA damage. Doxorubicin also generates free radicals, leading to oxidative stress and further damage to cancer cells. Due to its broad spectrum of activity, doxorubicin is utilized in combination with other chemotherapy drugs in various treatment regimens. However, it is associated with potential side effects, including cardiotoxicity, bone marrow suppression, and gastrointestinal disturbances.

Reference

1. Zykova MG, Medvedeva NV, Torkhovskaya TI, et al. Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model. Exp Oncol. 2012 Dec;34(4):323-6.
2. Patel S, Sprung AU, Keller BA, et al. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol Pharmacol. 1997 Oct;52(4):658-66.
3. Zeman SM, Phillips DR, Crothers DM. Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11561-5.
4. Pourquier P, Montaudon D, Huet S, et al. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death. Biochem Pharmacol. 1998 Jun 15;55(12):1963-71.
5. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999 Apr 1;57(7):727-41.